Genaissance Pharmaceuticals, Inc. announced that it has licensed its HAP technology to Novo Nordisk for use in a drug development programme. Under the terms of the agreement, Novo Nordisk will pay Genaissance license and service fees, including fees for genotyping clinical samples. Genaissance will have certain rights to develop and commercialize specified diagnostic products and services.

"We are pleased that Novo Nordisk chose our HAP technology to address their pharmacogenomic need," said Kevin Rakin, president and CEO of Genaissance Pharmaceuticals. "Novo Nordisk has been utilizing our Good Laboratory Practices DNA and genotyping services and this agreement expands the scope of our work with them, demonstrating how our various pharmacogenomic capabilities can benefit our customer base."

Novo Nordisk is a focused healthcare company and is involved in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. With headquarters in Denmark, Novo Nordisk employs approximately 18,700 people in 68 countries and markets its products in 179 countries.

Genaissance Pharmaceuticals, Inc. is involved in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance is headquartered in Science Park in New Haven, Connecticut.